Showing posts with label Antinuclear Antibody Testing Market. Show all posts
Showing posts with label Antinuclear Antibody Testing Market. Show all posts

Wednesday, February 12, 2020

Antinuclear Antibody Testing Market will be growing at a CAGR of 9.8% during the forecast 2017 To 2025

According to the latest market report published by Credence Research, Inc. “Antinuclear Antibody Tests Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025,” the global antinuclear antibody tests market was valued at US$ 649 Mn in 2016, and is expected to reach US$ 1,588.7 Mn by 2025, expanding at a CAGR of 9.8% from 2017 to 2025
Market Insights
Antinuclear antibody tests (ANA) are used to evaluate the quantity and pattern of antibodies in the blood. It is used to evaluate autoimmune disorders that might affect tissues and organs throughout the systemic body. It is commonly used to diagnose rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, scleroderma, and polymyositis. Usually, any foreign body such as a virus or bacteria if enters the body, would be destroyed by the immune system. In an autoimmune disorder, the body produces ANA as a group of antibodies, as the immune system is not able to differentiate between "self" and "nonself." It targets the nucleus of the cell and destroys the tissue and the organ. Rising prevalence of autoimmune disorders, advancement in lab automation and use of novel biomarker are the key factors driving the growth of antinuclear antibody tests market
Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/anti-nuclear-antibody-testing-ana-market
The global antinuclear antibody tests market is segmented by product type into reagent & assays kits, systems, and software & services. Reagents and assay kits occupy the largest share of the global antinuclear antibody tests market. The global antinuclear antibody tests market is segmented by technique type into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay and multiplex assay. Enzyme-Linked Immunosorbent Assay (ELISA) dominates the global antinuclear antibody tests market. By disease, global antinuclear antibody tests market is segmented into rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Rheumatoid arthritis currently occupies the largest market share of the global antibody tests market due to the rising prevalence of rheumatoid arthritis.
As of the current market scenario, North America dominated the global antinuclear antibody tests market followed by Europe. Factors contributing to the growth of the North American market include an increase in the prevalence of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), growing introduction and availability of novel diagnostic tools and supportive reimbursement policies. The Asia Pacific is the fastest growing regional market for antinuclear antibody tests.
Key Market Movements:
-  Rising awareness about autoimmune disorders and availability of novel diagnostic tools and kits also contribute to the growth of antinuclear antibody tests market
- The prevalence of diagnosed autoimmune conditions is highest in EU-5 with 9%, followed by China and the U.S. with 8% and 7% respectively. Autoimmune diseases are one of the leading cause of mortality in developed countries. Thus the rising prevalence of the autoimmune disorder is the pivotal factor driving the growth of antinuclear antibody tests market
Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58594
List of Companies Covered:
  • Alere, Inc.
  • Abbott Laboratories
  • Antibodies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biocom Biotech
  • Erba Diagnostics, Inc.
  • Euroimmun AG
  • HUMAN Diagnostics, Inc.
  • Immuno Concepts, Inc.
  • Inova Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech Plc
  • Zeus Scientific, Inc.
  • Other Notable Players
Market Segmentation:
By Product Type
  • Attractive Investment Proposition: Global Antinuclear Antibody Tests Market, by Product Type
  • Reagents & Assay Kits
  • Software & Services
  • Systems
By Technique Type
  • Attractive Investment Proposition: Global Antinuclear Antibody Tests Market, by Technique Type
  • ELISA
  • Immunofluorescence Assay
  • Multiplex Assay
By Disease Type
  • Attractive Investment Proposition: Global Antinuclear Antibody Tests Market, by Disease Type
  • Rheumatoid Arthritis
  • Scleroderma
  • Systemic Lupus Erythematosus
  • Sjögren’s Syndrome
  • Other Diseases
By Geography Segment Type
  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of the World (the Middle East & Africa, Latin America)
Access Free Sample Copy of Research Report: https://www.credenceresearch.com/sample-request/58594

Thursday, August 3, 2017

Global Antinuclear Antibody Testing Market Size, Share, Growth, Outlook and Forecast 2017 To 2025: Credence Research

According to the latest market report published by Credence Research, Inc. “Antinuclear Antibody Tests Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025,” the global antinuclear antibody tests market was valued at US$ 649 Mn in 2016, and is expected to reach US$ 1,588.7 Mn by 2025, expanding at a CAGR of 9.8% from 2017 to 2025
Browse the full report Antinuclear Antibody Tests Market - Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at http://www.credenceresearch.com/report/anti-nuclear-antibody-testing-ana-market
Market Insights
An antinuclear antibody tests (ANA) are used to evaluate quantity and pattern of antibodies in the blood. It is used to evaluate autoimmune disorders that might affect tissues and organ throughout systemic body. It is commonly used to diagnose rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, scleroderma and polymyositis. Usually any foreign body such as virus or bacteria if enters the body, would be destroyed by the immune system. In autoimmune disorder, body produces ANA as group of antibodies, as the immune system is not able to differentiate between "self" and "nonself." It targets the nucleus of the cell and destroys the tissue and the organ. Rising prevalence of autoimmune disorders, advancement in lab automation and use of novel biomarker are the key factors driving the growth of antinuclear antibody tests market
The global antinuclear antibody tests market is segmented by product type into reagent & assays kits, systems and software & services. Reagents and assay kits occupy the largest share of global antinuclear antibody tests market. The global antinuclear antibody tests market is segmented by technique type into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay and multiplex assay. Enzyme-Linked Immunosorbent Assay (ELISA) dominates the global antinuclear antibody tests market. By disease, global antinuclear antibody tests market is segmented into rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma and other diseases. Rheumatoid arthritis currently occupies the largest market share of global antibody tests market due to rising prevalence of rheumatoid arthritis.
As of the current market scenario, North America dominated the global antinuclear antibody tests market followed by the Europe. Factors contributing to the growth of North America market includes increase in prevalence of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), growing introduction and availability of novel diagnostic tools and supportive reimbursement policies. Asia Pacific is the fastest growing regional market for antinuclear antibody tests.
Market Competition Assessment:
Key players in the global antinuclear antibody test market are Alere, Inc., EUROIMMUN AG, ERBA Diagnostics, Inc., Trinity Biotech plc, Bio-Rad Laboratories, Inc., Immuno Concepts, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc. and others.
Key Market Movements:
-  Rising awareness about autoimmune disorders and availability of novel diagnostic tools and kits also contribute to the growth of antinuclear antibody tests market
- Prevalence of diagnosed autoimmune conditions is highest in EU-5 with 9%, followed by China and U.S. with 8% and 7% respectively. Autoimmune diseases is one of leading cause of mortality in developed countries. Thus rising prevalence of autoimmune disorder is the pivotal factor driving the growth of antinuclear antibody tests market
About Us:
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Contact:
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE,
CA 95103, United States
Ph: 1-800-361-8290

Bone Cement Market | Major players are Zimmer Biomet, Stryker Corporation, DePuy Synthes, Cook Medical, DePuy Synthes, Smith & Nephew

The latest market report published by Credence Research, Inc. “ Bone Cement Market  –  Growth, Future Prospects, and Competitive Analysis,...